Overview of FLUARIX QUADRIVALENT

Property	Description
Active Ingredient	Influenza virus hemagglutinin antigens
Form	Sterile suspension (for injection)
Pharmacological Class	Immunizing Agent / Viral Vaccine, Inactivated
Common Use	Prevention of seasonal influenza (flu)
Origin	Derived from influenza viruses propagated in embryonated chicken eggs

What Type of Immunizing Agent is FLUARIX QUADRIVALENT?

FLUARIX QUADRIVALENT is classified as a biological product and an inactivated seasonal influenza vaccine, formally recognized as an Immunizing Agent. This product is formulated as a sterile suspension intended for intramuscular injection to stimulate active immunity against the Influenza virus in individuals aged 6 months and older. The vaccine is categorized as quadrivalent because it covers components from four distinct virus strains, a design intended to provide protection against the range of circulating Influenza A and Influenza B viruses.

How is the Quadrivalent Composition Different?

The active ingredients consist of highly purified surface proteins, primarily hemagglutinin antigens, sourced from the four specific Influenza virus strains selected annually by global health authorities. The formulation is an inactivated split-virion product, which ensures the viral components cannot replicate or cause the flu illness. This approach, which utilizes only specific antigens suspended in an aqueous vehicle, is a standard manufacturing method employed to deliver the necessary antigenic stimulation without risk of infection.

What is the General Purpose of This Vaccine?

The general purpose of FLUARIX QUADRIVALENT is to reduce the risk of contracting the influenza illness caused by the four included strains during the flu season. By exposing the immune system to these inactivated viral fragments, the vaccine induces the production of specific protective antibodies in advance of natural exposure. This action establishes a state of active immunity, which serves as a prophylactic strategy for preventing outcomes associated with Influenza A and Influenza B infections.

What side effects are possible with FLUARIX QUADRIVALENT?

The safety profile for FLUARIX QUADRIVALENT details adverse reactions documented during clinical trials and post-marketing surveillance, classified by frequency according to regulatory standards (FDA, EMA).

Commonly Documented Adverse Reactions

Reactions classified as Very Common (occurring in 1 in 10 or more people) in adults typically include pain at the injection site, headache, muscle aches (myalgia), and fatigue. Reactions considered Common (occurring in 1 in 100 to less than 1 in 10 people) include injection site redness and swelling, arthralgia (joint pain), chills, and fever (pyrexia).

Adverse reactions are grouped into System-Organ Classes, with effects documented across General Disorders and Administration Site Conditions, Nervous System Disorders, Musculoskeletal and Connective Tissue Disorders, and Immune System Disorders.

Serious Safety Events and Special Populations

Serious adverse reactions reported during post-marketing surveillance are listed as having a Frequency Not Known (cannot be estimated from available data). These events include anaphylaxis (severe allergic reaction), Guillain-Barré Syndrome (GBS), and vasculitis (inflammation of blood vessels). Syncope (fainting) may occur in association with the procedure itself.

Safety information for specific populations is documented in regulatory labeling. In children (6 months through 5 years), very common systemic reactions include irritability, loss of appetite, and drowsiness. For immunosuppressed individuals, the immune response following administration may be lower.

Safety Restrictions

Regulatory documentation states the vaccine is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any vaccine component, including egg protein, or following a previous dose of any influenza vaccine. The decision to administer the vaccine to individuals with a prior history of GBS within six weeks of a previous influenza vaccination requires careful consideration.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory documentation for FLUARIX QUADRIVALENT, which is an inactivated viral vaccine, does not contain a dedicated section describing the symptoms or management of an overdose resulting from an excessive administered volume or dose. Regulatory focus for emergency action is instead centered on the management of severe acute reactions that may occur following a standard administration.

Documented Emergency Response

The most serious event requiring immediate preparedness, as documented in regulatory labeling, is the occurrence of a possible anaphylactic reaction. Anaphylaxis is a severe, life-threatening allergic response that requires urgent medical intervention, regardless of the dose administered.

Overdose Manifestation	Regulatory Documentation Status
Conventional Overdose Symptoms	Not documented in official labeling.
Life-Threatening Outcome	Anaphylactic reactions (requires preparedness).
Antidote	None specified.

When to Seek Urgent Medical Help

Official prescribing information mandates that appropriate medical treatment and supervision must be available immediately to manage any possible severe acute reactions, such as anaphylaxis, that may occur following the administration of FLUARIX QUADRIVALENT. Symptomatic and supportive treatment would be required in such an emergency. Users should seek immediate medical attention if they experience any signs of a severe allergic reaction after receiving the vaccine.

Therapeutic Uses of FLUARIX QUADRIVALENT

What FLUARIX QUADRIVALENT Treats: Main Uses and Benefits

FLUARIX QUADRIVALENT is a vaccine used for active immunization, which may assist with reducing the risk of seasonal influenza illness caused by the four specific virus strains it contains. This prophylactic therapeutic domain is relevant for all persons aged 6 months and older seeking to address the sudden onset of severe, acute symptoms. The vaccine is considered relevant in addressing the risk associated with Influenza A (subtypes H1N1 and H3N2) and Influenza B (two lineages).

The use of this vaccine may assist with reducing the risk of experiencing severe clinical outcomes. This supports the patient by being relevant for easing the potential for serious subsequent conditions, such as viral or bacterial pneumonia and acute bronchitis. This approach contributes to improved comfort by assisting individuals with the potential for severe muscle aches, high fever, and profound fatigue that often interfere with daily functioning.

Quick Fact: Support for Clinical Risk FLUARIX QUADRIVALENT is commonly used as an annual measure across diverse patient populations to support the overall reduction of risk associated with severe outcomes, including hospitalization, due to seasonal influenza.

Eligibility and Restrictions for Use

Population Eligibility for FLUARIX QUADRIVALENT

FLUARIX QUADRIVALENT is approved for use in persons aged 6 months and older for active immunization against influenza. Regulatory documents define specific populations who are prohibited from using the vaccine or who require special consideration.

Absolute Contraindications

Use is formally contraindicated in individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine.

Eligibility Restrictions and Limitations

Population Group	Regulatory Status
Children less than 6 months	Safety and effectiveness have not been established.
Pregnancy/Lactation	Safety and effectiveness have not been established in pregnant or nursing women.
GBS History	Use requires caution if Guillain-Barré syndrome (GBS) occurred within six weeks of a prior influenza vaccination.
Coagulation Disorders	Use requires caution in patients with thrombocytopenia or any coagulation disorder due to the risk of bleeding from intramuscular injection.

Vaccination should also be postponed in individuals with a moderate or severe acute febrile illness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory interaction profile for FLUARIX QUADRIVALENT is strictly defined by pharmacodynamic effects on the immune system and procedural requirements related to administration. The vaccine does not have documented drug-drug interactions involving common metabolic enzymes or drug transporters.

The profile identifies three main domains of interaction, classified as Use with Caution in the regulatory documents of government health agencies, including the FDA and EMA:

Immunosuppressive Agents: Co-administration with medicinal products that cause immunosuppression, such as high-dose corticosteroid therapy, may result in a lower immune response to the vaccine antigens. This is the formally documented pharmacodynamic outcome of this interaction.
Other Injectable Vaccines: When administered at the same visit as another injectable vaccine, the vaccines should always be administered at different injection sites. This procedural restriction is noted in regulatory text, as co-administration may increase the incidence of local adverse reactions.
Anticoagulant Therapy: Caution is required for individuals receiving anticoagulant therapy or those with bleeding disorders. This population-specific constraint relates to the intramuscular injection technique, which carries an official risk of hematoma at the injection site.

This profile confirms that interaction relevance is constrained to an altered immunocompetent state or the physical act of injection, reflecting the vaccine’s biological nature.

Mechanism of Action

FLUARIX QUADRIVALENT is an inactivated, split-virion influenza vaccine designed to elicit a protective immunological response. The mechanism is initiated by the four included hemagglutinin (HA) antigens, representing two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata).

Upon intramuscular administration, the HA antigens are recognized by antigen-presenting cells (APCs) in the local lymphatic system. This interaction involves the processing and presentation of the viral antigens to specific T- and B-lymphocytes. The engagement of these cells modulates the cellular immune pathway, leading to the activation and clonal expansion of B-cells.

This cellular cascade culminates in the differentiation of B-cells into plasma cells, which subsequently synthesize and release specific circulating IgG antibodies. This represents the primary system-level physiological consequence. These antibodies act as the effector molecules, binding directly to the HA surface structures of the homologous, wild-type influenza virus. This interaction neutralizes the virus by sterically blocking the HA-mediated attachment of the virion to host respiratory epithelial cells, preventing intracellular entry and replication.

Dosage and Administration Information

FLUARIX QUADRIVALENT is an inactivated influenza vaccine administered by intramuscular injection only and is approved for use in persons aged 6 months and older. It should not be administered intravenously, intradermally, or subcutaneously, and should be visually inspected for particulate matter or discoloration prior to administration. If these conditions exist, the vaccine should be discarded.

Dosage and Administration

The vaccine is supplied as a 0.5-mL single-dose injectable suspension. The appropriate dose and schedule vary by age and prior vaccination history:

Age Group	Vaccination Status	Dose and Schedule
6 months through 8 years	Not previously vaccinated	Two doses (0.5 mL each) at least 4 weeks apart
	Previously vaccinated in a prior season	One or two doses (0.5 mL each)
9 years and older	Not applicable	One 0.5-mL dose

For administration, the syringe should be shaken well before use. The preferred injection sites are the anterolateral thigh for children aged 6 through 11 months, and the deltoid muscle of the upper arm for persons aged 12 months and older with adequate muscle mass.

Storage

The vaccine must be stored refrigerated between 36°F and 46°F (2°C and 8°C). It is critical that the vaccine not be frozen, and any vaccine that has been frozen must be discarded.

Recent Clinical Evidence

Research evidence / Overview of studies for FLUARIX QUADRIVALENT

Evidence for the Prevention of Seasonal Influenza Illness

Research has explored studies that evaluated clinical outcomes related to the occurrence of illness caused by the four specific influenza virus strains contained in the annual formula. The evidence base includes randomized controlled trials (RCTs) applied in research contexts involving both healthy adults and adolescents. These studies were designed to evaluate clinical endpoints related to the occurrence of illness and the immune system response.

Studies examined clinical outcomes, including the measurement of the incidence of laboratory-confirmed influenza illness during a flu season. Findings describe patterns observed related to the occurrence of influenza illness, including severe illness, compared to control groups. Separately, research has explored immunogenicity by tracking antibody levels. Studies monitored whether the immune response generated by this formulation was comparable, or non-inferior, to the response generated by comparator licensed influenza vaccines. These findings indicate that non-inferiority criteria were generally met across the populations studied.

Studies in Specific Age Groups

Research has been conducted across the entire approved age range. Studies explored the vaccine's use in children aged 6 months through 17 years, examining outcomes related to physical discomfort and immune response. For older adults (aged 50 and older), findings indicate that antibody responses measured in geriatric subjects were reported to show patterns different from those observed in younger subjects evaluated in the research.

Research describes that the measured immune response in individuals receiving immunosuppressive therapy or those with an altered immune system was studied for patterns that differed from those observed in healthy persons. Additionally, specific studies focusing on clinical outcomes related to pregnancy were not available in the initial trials, which led to the establishment of ongoing monitoring programs that track outcomes in this group.

Research on Durability and Follow-Up Period

The primary goal of the clinical trials was to assess outcomes over a defined time interval: a duration of approximately six months, which aligns with an influenza season. Research has explored short-term symptom changes, but limited information for long-term outcomes extending beyond one season is available. Since the influenza virus changes annually, the research focus is on seasonal protection.

Evidence Gaps and Research Uncertainties

For certain age groups, the required evidence for the vaccine was substantially supported by immunogenicity studies (measuring antibody levels) rather than direct clinical efficacy trials specifically powered to measure a reduction in laboratory-confirmed illness. While studies suggest an association between achieving a certain antibody level and clinical outcomes, the certainty remains low regarding the predictive value of the exact antibody threshold for every individual. Studies indicate that the findings observed apply only to the specific influenza season and strains studied, as the measured incidence of illness is subject to annual variation based on how closely the vaccine strains match the strains circulating in the community that year.

Frequently Asked Questions (FAQ)

Common questions about FLUARIX QUADRIVALENT (FAQ)

Q: Is FLUARIX QUADRIVALENT the same as the regular flu shot?

Official documents describe FLUARIX QUADRIVALENT as a specific brand of inactivated (non-live) influenza vaccine. It is categorized as 'quadrivalent,' meaning it is formulated to protect against four strains of the influenza virus. Official guidance on flu prevention generally focuses on recommending an annual vaccine, such as this one.

Q: How quickly does FLUARIX QUADRIVALENT start working after getting it?

According to official information, the body's immune system typically requires time to build a protective response. Protection is generally achieved approximately 2 weeks following the time of administration.

Q: Why do official documents mention that FLUARIX QUADRIVALENT does not treat existing flu?

Official regulatory documents state that the purpose of this product is active immunization for prevention of influenza. It is classified as a prophylactic agent, meaning it works to help prevent future illness, and is not designed or indicated to treat an active or existing flu infection.

Q: Are there different formulations of FLUARIX QUADRIVALENT?

The official product information specifies a single-dose volume of 0.5-mL injectable suspension. The regulatory label describes only this formulation for FLUARIX QUADRIVALENT. Other products under different brand names or with different components may be available, but this vaccine is specifically available in this form.

Q: What are the ingredients in FLUARIX QUADRIVALENT besides the active components?

In addition to the active influenza antigens, the suspension contains non-active ingredients such as octoxynol-10 and polysorbate 80. Furthermore, residual amounts of substances used during manufacturing, including formaldehyde, hydrocortisone, and ovalbumin, may be present in the final product.

Q: Does FLUARIX QUADRIVALENT contain mercury or thimerosal?

Official product documentation states that this formulation of FLUARIX QUADRIVALENT is manufactured without thimerosal being used as a preservative.

Q: Does FLUARIX QUADRIVALENT contain any antibiotics?

According to the product description, residual amounts of the antibiotic gentamicin sulfate may be present from the manufacturing process.

Q: Does FLUARIX QUADRIVALENT contain preservatives?

Official regulatory documents confirm that FLUARIX QUADRIVALENT is formulated without preservatives.

Q: Are there any specific restrictions on activities immediately after receiving FLUARIX QUADRIVALENT?

The Warnings section in the regulatory label mentions the possibility of syncope (fainting) occurring in association with the procedure itself. Due to this potential reaction, procedures are typically in place to ensure that any person who faints does not injure themselves.

Q: Does FLUARIX QUADRIVALENT have a specific manufacturer that is always mentioned in official texts?

Official regulatory information indicates that the manufacturer of this product is GlaxoSmithKline (GSK).

Q: Is there a link between FLUARIX QUADRIVALENT and common seasonal colds?

The purpose of the vaccine is to provide protection against the specific influenza virus strains it contains. Official public health information clarifies that this product will not protect against the common cold or other illnesses not caused by the flu.

Q: Is FLUARIX QUADRIVALENT a prescription-only product?

Yes, FLUARIX QUADRIVALENT is formally classified as a prescription-only biological product.

Q: Does FLUARIX QUADRIVALENT protect against all types of flu?

No, the vaccine is specifically designed to provide protection against the four influenza virus strains included in the formulation for that particular season. It is not formulated to protect against all possible circulating influenza strains or other types of viral infections.

Q: Is it true that FLUARIX QUADRIVALENT is only for use in a specific time of year?

Use of the vaccine is typically associated with the annual influenza season. This is because the protective immunity can decline over time, and the formulation is updated annually to match the strains predicted to be circulating each year.

Q: Can people with long-term health conditions generally receive FLUARIX QUADRIVALENT?

Official information notes that individuals with chronic health conditions are often considered a high-priority group for vaccination. For those receiving immunosuppressive therapy, regulatory documents indicate that the immune response to the vaccine may be lower than the response observed in healthy persons.

Q: Why is annual use of FLUARIX QUADRIVALENT often discussed?

Annual use is generally discussed for two main reasons. Firstly, a person’s protective immune response naturally declines over time. Secondly, the influenza virus strains change yearly, which requires the vaccine's composition to be updated each season to offer the most relevant protection.

Q: What is the process for monitoring the safety of FLUARIX QUADRIVALENT after it's approved?

The safety of the vaccine is continuously tracked through postmarketing surveillance. This involves monitoring data gathered after the product is released for public use, often relying on systems like the Vaccine Adverse Events Reporting System (VAERS) for reporting potential reactions.

Q: Does the name FLUARIX QUADRIVALENT refer to a specific brand or type of vaccine?

FLUARIX QUADRIVALENT is the brand name given to this specific inactivated influenza virus vaccine product. The term 'quadrivalent' refers to the type, indicating its formulation contains four virus strains.

Q: What is the difference between quadrivalent and trivalent flu vaccines?

The difference is in the number of influenza B strains they contain. A quadrivalent vaccine is formulated with antigens for two influenza A strains and two influenza B strains. A trivalent vaccine contains two influenza A strains and only one influenza B strain.

Q: Are there specific symptoms that should prompt someone to seek immediate attention after receiving FLUARIX QUADRIVALENT?

Official warnings indicate that immediate medical attention is necessary for symptoms of a severe allergic reaction (anaphylaxis), such as difficulty breathing, swelling of the face or throat, or hives. Other serious adverse events, like Guillain-Barré syndrome (GBS), have been reported in post-marketing surveillance. These situations generally require immediate assessment by a healthcare provider.

Q: Is it common for people to not feel any side effects from FLUARIX QUADRIVALENT?

Clinical trials tracked the percentage of people who experienced specific adverse reactions, with injection site pain and general symptoms like fatigue being reported as common. However, the regulatory documentation does not explicitly state the percentage of individuals who reported having zero side effects during the trials.

Q: How is the specific formulation of FLUARIX QUADRIVALENT decided for each flu season?

The influenza virus strains included in the formulation are decided annually by global and national health authorities. This decision is based on the official recommendations for the upcoming flu season from bodies such as the World Health Organization (WHO).

Q: What are the general guidelines for use during the flu season related to FLUARIX QUADRIVALENT?

The vaccine is approved for use in individuals who are 6 months of age and older. The specific dosing requirements and the best time for administration are generally aligned with the annual recommendations issued by public health bodies like the Advisory Committee on Immunization Practices (ACIP).

Q: Is there official information available about the effectiveness rate of FLUARIX QUADRIVALENT?

Official sources clarify that the effectiveness can vary each season. This variability depends on factors such as how closely the vaccine strains match the influenza strains circulating that year, as well as the age and general health of the person receiving the vaccine. A single fixed rate is not provided in the regulatory information.

How should FLUARIX QUADRIVALENT be stored and disposed of?

FLUARIX QUADRIVALENT must be stored under controlled conditions to maintain its effectiveness, according to official regulatory labeling.

Official Storage and Handling

Storage Requirement	Classification	Constraint
Temperature	Refrigerated	Maintain between 2 C and 8 C (36 F and 46 F).
Freezing	Prohibited	Do not freeze; discard the product if it has been frozen.
Protection	Protect from light	Store in the original package until use.

Disposal Requirements

Official instructions mandate that the unused, expired, or frozen product must be disposed of in accordance with local requirements for pharmaceutical waste. Used prefilled syringes and needles must be immediately placed in a labeled, puncture-proof sharps container. The product must also be kept out of the sight and reach of children.

FLUARIX QUADRIVALENT